Matthew Greenwood

Associate Professor Matthew Greenwood is an academic researcher specializing in hematopoietic stem cell transplantation and its long-term outcomes. His work focuses on clinical trials, infection management, survivorship care, and psychosocial impacts in transplant recipients. He has contributed to consensus statements on therapeutics and vaccination protocols during the pandemic, emphasizing care for immunocompromised patients.

Research Interests: His studies address challenges in transplantation medicine, including graft versus host disease prevention, post-transplant infection control (e.g., CMV, EBV), cost-effectiveness of transplant procedures, and quality of life among survivors. He also examines treatment strategies for hematological malignancies in unique populations such as pregnant women and adolescents.

• Co-led the ANZHIT-1 study on calcineurin inhibitor reduction in haploidentical transplants
• Authored guidelines on COVID-19 therapeutics for haematological patients
• Investigated Epstein-Barr virus risks and prophylaxis strategies
• Explored decisional regret and quality of life in transplant survivors

Grants: He secured a National Health and Medical Research Council (NHMRC) grant in 2022 for studying regulatory T cell mechanisms in transplantation.

Labs/Teams: Collaborates with the Australasian Lymphoma Alliance, Bone Marrow Transplant Society of Australia and New Zealand, and institutions in Sydney, Australia, focusing on translational and clinical research in haematology.